Capricor Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted explicit 10-year cash-flow DCF for lead candidate deramiocel (Duchenne muscular dystrophy cardiomyopathy), currently under FDA BLA review: risk-adjusted cash flows of -$20M (yr1) ramping to a risk-adjusted $150-160M by yrs5-10, reflecting a higher-than-typical probability of approval given its late regulatory-review stage; 12% discount rate; 2% terminal growth; -$146.9M net cash; 58.14M shares outstanding.

Reasoning: Capricor's lead program is under active FDA review (BLA, with an extended PDUFA date) rather than in early clinical trials, so a risk-adjusted NPV with a higher probability-of-success weighting than a typical Phase 2 program is the most appropriate method; cash is added back directly.